CR6614A - Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural gaba - Google Patents

Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural gaba

Info

Publication number
CR6614A
CR6614A CR6614A CR6614A CR6614A CR 6614 A CR6614 A CR 6614A CR 6614 A CR6614 A CR 6614A CR 6614 A CR6614 A CR 6614A CR 6614 A CR6614 A CR 6614A
Authority
CR
Costa Rica
Prior art keywords
structural analog
synthetic combinations
gaba
antagonist
receiver antagonist
Prior art date
Application number
CR6614A
Other languages
English (en)
Inventor
Hughes John
Singh Lakhbir
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CR6614A publication Critical patent/CR6614A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Un metodo para impedir o tratar el dolor cronico, administrando a un paciente que necesita el tratamiento, una cantidad efectiva de una combinacion sinergistica de un antagonista de receptor de NK1 y un analogo de gaba, donde la razon del analogo de gaba al antagonista de receptor de NK1 es de 50:1 a 1:1 expresado como partes en peso y de NK1 es de 20:1 expresado como partes en peso.
CR6614A 1999-10-07 2002-04-05 Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural gaba CR6614A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07

Publications (1)

Publication Number Publication Date
CR6614A true CR6614A (es) 2003-12-04

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6614A CR6614A (es) 1999-10-07 2002-04-05 Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural gaba

Country Status (38)

Country Link
EP (2) EP1221950B1 (es)
JP (2) JP2003510356A (es)
KR (1) KR20020060192A (es)
CN (1) CN1387434A (es)
AP (1) AP2002002501A0 (es)
AR (1) AR029646A1 (es)
AT (1) ATE269072T1 (es)
AU (2) AU7663300A (es)
BG (1) BG106548A (es)
BR (1) BR0014598A (es)
CA (1) CA2385930A1 (es)
CO (1) CO5280195A1 (es)
CR (1) CR6614A (es)
CZ (1) CZ20021116A3 (es)
DE (1) DE60011650T2 (es)
DK (1) DK1221950T3 (es)
EA (1) EA004266B1 (es)
EE (1) EE200200185A (es)
ES (1) ES2220542T3 (es)
GT (1) GT200000166A (es)
HR (1) HRP20020286A2 (es)
HU (1) HUP0203466A3 (es)
IL (1) IL148965A0 (es)
IS (1) IS6318A (es)
MA (1) MA26826A1 (es)
MX (1) MXPA02003484A (es)
NO (1) NO20021625D0 (es)
NZ (1) NZ517949A (es)
OA (1) OA12063A (es)
PA (1) PA8504301A1 (es)
PE (1) PE20010708A1 (es)
PL (1) PL357498A1 (es)
PT (1) PT1221950E (es)
SK (1) SK4542002A3 (es)
TR (1) TR200200913T2 (es)
UY (1) UY26376A1 (es)
WO (2) WO2001024792A1 (es)
ZA (1) ZA200202675B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1094757C (zh) 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1499309A4 (en) * 2002-04-24 2008-05-28 Cypress Bioscience Inc PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES
US20060039968A1 (en) * 2002-10-08 2006-02-23 Ramalingam Manikandan Gabapentin tablets and method for their preparation
EP1721607A1 (en) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
KR101786818B1 (ko) 2010-07-30 2017-10-18 도레이 카부시키가이샤 신경장애성 동통의 치료제 또는 예방제
US9089531B2 (en) * 2010-09-28 2015-07-28 The Regents Of The University Of California GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
JP2001502311A (ja) * 1996-10-07 2001-02-20 メルク シヤープ エンド ドーム リミテツド 抗鬱及び／又は抗不安薬としてのｃｎｓ浸透性ｎｋ―１受容体拮抗薬
AU729708B2 (en) * 1996-12-02 2001-02-08 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating severe anxiety disorders

Also Published As

Publication number Publication date
SK4542002A3 (en) 2003-09-11
HRP20020286A2 (en) 2003-08-31
GT200000166A (es) 2002-03-30
MA26826A1 (fr) 2004-12-20
MXPA02003484A (es) 2004-09-10
EP1233766A1 (en) 2002-08-28
EP1221950B1 (en) 2004-06-16
CA2385930A1 (en) 2001-04-12
AU1696201A (en) 2001-05-10
BG106548A (en) 2002-12-29
HUP0203466A2 (hu) 2003-02-28
ZA200202675B (en) 2003-04-15
NO20021625L (no) 2002-04-05
IL148965A0 (en) 2002-11-10
NZ517949A (en) 2003-08-29
AU7663300A (en) 2001-05-10
IS6318A (is) 2002-03-21
PA8504301A1 (es) 2002-08-26
DK1221950T3 (da) 2004-09-20
DE60011650T2 (de) 2005-07-14
JP2003510356A (ja) 2003-03-18
AR029646A1 (es) 2003-07-10
BR0014598A (pt) 2002-06-11
OA12063A (en) 2006-05-03
JP2003510355A (ja) 2003-03-18
CZ20021116A3 (cs) 2003-05-14
PT1221950E (pt) 2004-08-31
ES2220542T3 (es) 2004-12-16
AP2002002501A0 (en) 2002-06-30
WO2001024791A1 (en) 2001-04-12
EA200200303A1 (ru) 2002-08-29
EA004266B1 (ru) 2004-02-26
UY26376A1 (es) 2000-12-29
EP1221950A1 (en) 2002-07-17
PE20010708A1 (es) 2001-07-27
PL357498A1 (en) 2004-07-26
DE60011650D1 (de) 2004-07-22
CO5280195A1 (es) 2003-05-30
HUP0203466A3 (en) 2005-03-29
WO2001024792A1 (en) 2001-04-12
NO20021625D0 (no) 2002-04-05
KR20020060192A (ko) 2002-07-16
TR200200913T2 (tr) 2002-09-23
ATE269072T1 (de) 2004-07-15
CN1387434A (zh) 2002-12-25
EE200200185A (et) 2003-04-15
WO2001024792A9 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
CR6614A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural gaba
CO5660274A2 (es) Metodos terapeuticos y profilacticos para desordenes neuromusculares
ES2196361T3 (es) Combinaciones terapeuticas de antagonistas de rar y agonistas de rxr.
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
AR077573A2 (es) Uso de un inhibidor de tnf y composicion farmaceutica que lo comprende
EE200200107A (et) Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks
HK1044333A1 (zh) 趨化因子受體拮抗劑及其使用方法
BR0010669A (pt) Método para o tratamento de fibrose usando um antagonista da subunidade alfa-4 da integrina
ATE414522T1 (de) Verfahren zur behandlung von akuter und durch übermässige beanspruchung verursachter zerrung und verstauchung mit hyaluronsäure
EA201992759A1 (ru) Ассоциация, включающая кислород и гиалуроновую кислоту, для местного вагинального применения
UA87980C2 (ru) Композиция для улучшения познания и памяти
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
BR9708525A (pt) Método de tratamento de insuficência cardíaca com antagonistas de endotelina
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol
AR015537A1 (es) Uso de brinzolamida para la manufactura de un medicamento para tratar o prevenir edema de retina.
ES2168772T3 (es) Uso de hormona del crecimiento en composiciones para el tratamiento de la resistencia del corazon a la insulina.
BR112023023534A2 (pt) Composição farmacêutica para uso no tratamento de infarto cererbral
AR016067A1 (es) Una composicion anti-pie de atleta, utilizacion de lactosacarosa para preparar una composicion anti-pie de atleta y un metodo para preparar una composicionanti-pie de atleta
ES2062752T3 (es) Preparado de una sal de oxipurinol en forma oral para el tratamiento de hiperuricemia.
AR013424A1 (es) Uso de uridina para la preparacion de una composicion farmaceutica util para inhibir la toxicidad de los analogos de pirimidina
CR6602A (es) Metodos de uso de inhbidores selectivos de reasorcion de serotonina de rapido inicio, para tratar la disfuncion sexual
ECSP003696A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)